Outpatient administration of xaluritamig for mCRPC: Feasibility and safety
Outpatient administration of xaluritamig for mCRPC: Feasibility and safety
Long-term survival benefits of abiraterone in de novo metastatic prostate cancer
ESMO 2026: Highlights and analysis
TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer
AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer
Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results
ASCO 2026: Highlights and analysis
Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer
Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer
mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity
Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer
ASCO GU 2026: Updates in metastatic prostate cancer